5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients

Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response. We util...

Full description

Saved in:
Bibliographic Details
Published in:Clinical epigenetics 2021-02, Vol.13 (1), p.33-33, Article 33
Main Authors: Chen, Hang-Yu, Zhang, Wei-Long, Zhang, Lei, Yang, Ping, Li, Fang, Yang, Ze-Ruo, Wang, Jing, Pang, Meng, Hong, Yun, Yan, Changjian, Li, Wei, Liu, Jia, Xu, Nuo, Chen, Long, Xiao, Xiu-Bing, Qin, Yan, He, Xiao-Hui, Liu, Hui, Zhu, Hai-Chuan, He, Chuan, Lin, Jian, Jing, Hong-Mei
Format: Article
Language:English
Subjects:
Analysis
Anthracyclines
B-cell lymphoma
Blood
Cancer
Care and treatment
Chemotherapy
Corticosteroids
Cyclophosphamide
Deoxyribonucleic acid
DNA
DNA methylation
Doxorubicin
Epigenetic inheritance
Epigenetics
Gene expression
Genomes
Genomics
Lymphoma
Lymphomas
Medical prognosis
Monoclonal antibodies
Patients
Plasma
Prednisone
Rituximab
Targeted cancer therapy
Vincristine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response. We utilized 5hmC-Seal to generate genome-wide 5hmC profiles in plasma cell-free DNA (cfDNA) from 86 DLBCL patients before they received R-CHOP chemotherapy. To investigate the correlation between 5hmC modifications and curative effectiveness, we separated patients into training (n = 56) and validation (n = 30) cohorts and developed a 5hmC-based logistic regression model from the training cohort to predict the treatment response in the validation cohort. In this study, we identified thirteen 5hmC markers associated with treatment response. The prediction performance of the logistic regression model, achieving 0.82 sensitivity and 0.75 specificity (AUC = 0.78), was superior to existing clinical indicators, such as LDH and stage. Our findings suggest that the 5hmC modifications in cfDNA at the time before R-CHOP treatment are associated with treatment response and that 5hmC-Seal may potentially serve as a clinical-applicable, minimally invasive approach to predict R-CHOP treatment response for DLBCL patients.
ISSN:1868-7075
1868-7083
1868-7083
1868-7075
DOI:10.1186/s13148-020-00973-8